Article

Cross-neutralization antibodies against SARS-CoV-2 and RBD mutations from convalescent patient antibody libraries

2020-06-06

Abstract excerpt

The emergence of coronavirus disease 2019 (COVID-19) pandemic led to an urgent need to develop therapeutic interventions. Among them, neutralizing antibodies play crucial roles for preventing viral infections and contribute to resolution of infection. Here, we describe the generation of antibody libraries from 17 different COVID-19 recovered patients and screening of neutralizing antibodies to SARS-CoV-2. After 3...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: bd167b9e-d593-5096-ae93-5b35b8f4ff80
DOI: 10.1101/2020.06.06.137513

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Cross-neutralization antibodies against SARS-CoV-2 and RBD mutations from convalescent patient antibody librariesDOI 10.1101/2020.06.06.137513Read

Bivalent binding of a fully human IgG to the SARS-CoV-2 spike proteins reveals mechanisms of potent neutralizationSemantic proximity Read

Antibody Cocktail Exhibits Broad Neutralization against SARS-CoV-2 and SARS-CoV-2 variantsSemantic proximity Read

Profiling B cell immune responses to identify neutralizing antibodies from convalescent COVID-19 patientsSemantic proximity Read

A SARS-CoV-2 Neutralizing Antibody Selected from COVID-19 Patients by Phage Display is Binding to the ACE2-RBD Interface and is Tolerant to Known RBD MutationsSemantic proximity Read

SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.Semantic proximity Read

Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylacticsSemantic proximity Read

SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interfaceSemantic proximity Read

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations.Semantic proximity Read

A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients by phage display is binding to the ACE2-RBD interface and is tolerant to most known recently emerging RBD mutationsSemantic proximity Read

Neutralizing antibodies targeting SARS-CoV-2 spike proteinSemantic proximity Read

A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2Semantic proximity Read

A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike proteinSemantic proximity Read